Mirabella Financial Services LLP Has $20.59 Million Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Mirabella Financial Services LLP increased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 21.4% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 33,281 shares of the medical research company's stock after purchasing an additional 5,866 shares during the period. Thermo Fisher Scientific makes up about 1.3% of Mirabella Financial Services LLP's holdings, making the stock its 18th biggest position. Mirabella Financial Services LLP's holdings in Thermo Fisher Scientific were worth $20,587,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of TMO. Fisher Asset Management LLC grew its stake in shares of Thermo Fisher Scientific by 2.6% in the 3rd quarter. Fisher Asset Management LLC now owns 2,636,558 shares of the medical research company's stock valued at $1,630,896,000 after buying an additional 65,586 shares during the period. Ameriprise Financial Inc. raised its holdings in Thermo Fisher Scientific by 32.2% during the second quarter. Ameriprise Financial Inc. now owns 2,481,257 shares of the medical research company's stock worth $1,372,157,000 after buying an additional 604,895 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Thermo Fisher Scientific by 2.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,443,937 shares of the medical research company's stock worth $1,511,746,000 after acquiring an additional 61,017 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in Thermo Fisher Scientific by 1.2% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,740,482 shares of the medical research company's stock valued at $962,482,000 after purchasing an additional 20,075 shares during the last quarter. Finally, Unisphere Establishment raised its stake in shares of Thermo Fisher Scientific by 7.1% in the second quarter. Unisphere Establishment now owns 1,500,000 shares of the medical research company's stock worth $829,500,000 after purchasing an additional 100,000 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on TMO. Bernstein Bank increased their price target on Thermo Fisher Scientific from $565.00 to $625.00 and gave the company a "market perform" rating in a research report on Tuesday, October 22nd. JPMorgan Chase & Co. raised their price target on shares of Thermo Fisher Scientific from $650.00 to $670.00 and gave the company an "overweight" rating in a research report on Friday, September 20th. Morgan Stanley boosted their target price on Thermo Fisher Scientific from $655.00 to $680.00 and gave the stock an "overweight" rating in a research note on Friday, September 20th. Bank of America raised their price objective on shares of Thermo Fisher Scientific from $600.00 to $675.00 and gave the stock a "buy" rating in a report on Monday, September 16th. Finally, Evercore ISI decreased their price target on shares of Thermo Fisher Scientific from $630.00 to $620.00 and set an "outperform" rating for the company in a research note on Thursday, October 24th. Four investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of "Moderate Buy" and an average price target of $649.33.

Insider Buying and Selling

In related news, EVP Gianluca Pettiti sold 300 shares of the firm's stock in a transaction on Friday, October 25th. The shares were sold at an average price of $560.16, for a total value of $168,048.00. Following the completion of the transaction, the executive vice president now directly owns 16,663 shares of the company's stock, valued at approximately $9,333,946.08. This trade represents a 1.77 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Marc N. Casper sold 9,000 shares of the company's stock in a transaction on Friday, November 8th. The shares were sold at an average price of $552.86, for a total transaction of $4,975,740.00. Following the sale, the chief executive officer now directly owns 14,608 shares in the company, valued at approximately $8,076,178.88. The trade was a 38.12 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 37,150 shares of company stock valued at $20,651,865. 0.34% of the stock is owned by company insiders.

Thermo Fisher Scientific Stock Down 0.6 %

Shares of NYSE:TMO opened at $513.26 on Monday. Thermo Fisher Scientific Inc. has a 12-month low of $480.57 and a 12-month high of $627.88. The stock has a market capitalization of $196.32 billion, a price-to-earnings ratio of 32.18, a PEG ratio of 3.39 and a beta of 0.79. The stock has a fifty day simple moving average of $575.70 and a two-hundred day simple moving average of $580.20. The company has a current ratio of 1.63, a quick ratio of 1.26 and a debt-to-equity ratio of 0.64.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, beating the consensus estimate of $5.25 by $0.03. The company had revenue of $10.60 billion for the quarter, compared to analysts' expectations of $10.63 billion. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. Thermo Fisher Scientific's revenue was up .2% compared to the same quarter last year. During the same period last year, the firm posted $5.69 earnings per share. On average, research analysts anticipate that Thermo Fisher Scientific Inc. will post 21.67 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 15th. Stockholders of record on Friday, December 13th will be given a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.30%. The ex-dividend date of this dividend is Friday, December 13th. Thermo Fisher Scientific's payout ratio is 9.78%.

Thermo Fisher Scientific declared that its Board of Directors has approved a share buyback plan on Friday, November 15th that allows the company to repurchase $4.00 billion in shares. This repurchase authorization allows the medical research company to buy up to 2% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company's management believes its shares are undervalued.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.